at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Company profile
Ticker
ILMN
Exchange
Website
CEO
Francis deSouza
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ILLUMINA INC
SEC CIK
Corporate docs
Subsidiaries
Advanced Liquid Logic Inc. • BlueBee Holding BV • Conexio Genomics Pty Ltd. • Emedgene Technologies Ltd • GRAIL, LLC • IDbyDNA Inc. • Illumina AB • Illumina Australia • Illumina Austria GmbH • Illumina Belgium BV ...
IRS number
330804655
ILMN stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
12 Apr 24
8-K
Jakob Wedel Chief Strategy and Corporate Development Officer
9 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
10-K
2023 FY
Annual report
16 Feb 24
8-K
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
8 Feb 24
8-K/A
Cost Associated with Exit or Disposal Activities
9 Jan 24
8-K
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
9 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
Transcripts
ILMN
Earnings call transcript
2023 Q4
8 Feb 24
ILMN
Earnings call transcript
2023 Q3
9 Nov 23
ILMN
Earnings call transcript
2023 Q2
9 Aug 23
ILMN
Earnings call transcript
2023 Q1
25 Apr 23
ILMN
Earnings call transcript
2022 Q4
7 Feb 23
ILMN
Earnings call transcript
2022 Q3
4 Nov 22
ILMN
Earnings call transcript
2022 Q2
11 Aug 22
ILMN
Earnings call transcript
2022 Q1
6 May 22
ILMN
Earnings call transcript
2021 Q4
11 Feb 22
ILMN
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 927.00 mm | 927.00 mm | 927.00 mm | 927.00 mm | 927.00 mm | 927.00 mm |
Cash burn (monthly) | 208.67 mm | 6.08 mm | 260.67 mm | 93.08 mm | (no burn) | (no burn) |
Cash used (since last report) | 1.42 bn | 41.37 mm | 1.77 bn | 633.08 mm | n/a | n/a |
Cash remaining | -492.19 mm | 885.63 mm | -845.85 mm | 293.92 mm | n/a | n/a |
Runway (months of cash) | -2.4 | 145.6 | -3.2 | 3.2 | n/a | n/a |
Institutional ownership, Q4 2023
64.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 621 |
Opened positions | 104 |
Closed positions | 283 |
Increased positions | 199 |
Reduced positions | 241 |
13F shares | Current |
---|---|
Total value | 12.32 tn |
Total shares | 102.07 mm |
Total puts | 619.80 k |
Total calls | 1.08 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.18 mm | $2.53 tn |
Edgewood Management | 6.88 mm | $957.76 bn |
STT State Street | 6.72 mm | $936.20 bn |
Baillie Gifford & Co | 5.28 mm | $734.60 bn |
Growth Fund Of America | 4.99 mm | $1.50 bn |
Loomis Sayles & Co L P | 4.42 mm | $616.09 mm |
MS Morgan Stanley | 3.70 mm | $514.94 bn |
Wellington Management | 3.24 mm | $451.00 bn |
BK Bank Of New York Mellon | 2.91 mm | $404.93 bn |
IVZ Invesco | 2.61 mm | $363.26 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Carissa Rollins | Common Stock | Payment of exercise | Dispose F | No | No | 127.75 | 122 | 15.59 k | 11,746 |
28 Mar 24 | Ullem Scott B. | Common Stock | Grant | Acquire A | No | No | 137.682 | 163 | 22.44 k | 1,670 |
5 Mar 24 | Scott D Ericksen | Common Stock | Grant | Acquire A | No | No | 0 | 2,971 | 0.00 | 10,704 |
5 Mar 24 | Scott D Ericksen | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 1,486 | 0.00 | 1,486 |
5 Mar 24 | Scott D Ericksen | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 1,486 | 0.00 | 1,486 |
5 Mar 24 | Kevin Carl Pegels | Common Stock | Grant | Acquire A | No | No | 0 | 5,569 | 0.00 | 16,846 |
5 Mar 24 | Kevin Carl Pegels | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 6,497 | 0.00 | 6,497 |
5 Mar 24 | Kevin Carl Pegels | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 6,497 | 0.00 | 6,497 |
5 Mar 24 | Kathryne Gambrell Reeves | Common Stock | Grant | Acquire A | No | No | 0 | 5,569 | 0.00 | 17,965 |
5 Mar 24 | Kathryne Gambrell Reeves | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 6,497 | 0.00 | 6,497 |
News
Looking Into Illumina's Recent Short Interest
12 Apr 24
EU Approved Illumina's Plan To Divest Grail
12 Apr 24
Barclays Maintains Underweight on Illumina, Raises Price Target to $100
10 Apr 24
Stephens & Co. Reiterates Overweight on Illumina, Maintains $170 Price Target
10 Apr 24
RBC Capital Reiterates Outperform on Illumina, Maintains $253 Price Target
9 Apr 24
Press releases
Illumina's planned divestment of GRAIL approved by the European Commission
12 Apr 24
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
11 Apr 24
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
9 Apr 24
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
4 Apr 24
ILLUMINA ALERT: Bragar Eagel & Squire, P.C. is Investigating Illumina, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
26 Feb 24